JMP Securities initiated coverage of Instil Bio (TIL) with a Market Perform rating and no price target Instil Bio enters the :competitive landscape in last place but with a differentiated molecule,” the analyst tells investors in a research note. The firm sees the shares as fairly valued currently. It notes the company has very little clinical data outside the best objective response rate of 46% in 23 patients
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIL:
- Baird positive on Instil Bio’s SYN-2510 development strategy
- Instil Bio Outlines Oncology Strategy and Collaborative Efforts
- Instil Bio price target raised to $120 from $40 at H.C. Wainwright
- Instil Bio, ImmuneOnco announce registrational strategy for SYN-2510/IMM2510
- Boeing factory workers strike halts 737 MAX production: Morning Buzz